Navigation Links
Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
Date:9/18/2007

F="http://www.millennium.com" target="_new">http://www.millennium.com . Following the webcast, an archived version of the call will be available at the same address for 30 days.

About Multiple Myeloma

Multiple myeloma is the second most common hematologic malignancy and although the disease is predominantly a cancer of the elderly (the average age of onset is 65 to 70 years of age), recent statistics indicate both increasing incidence and younger age of onset. In the U.S., more than 50,000 individuals have MM and 20,000 new cases are diagnosed each year. Worldwide there are approximately 74,000 new cases and over 45,000 deaths annually.

About VELCADE

VELCADE is being co-developed by Millennium Pharmaceuticals, Inc. and JJPRD. Millennium is responsible for commercialization of VELCADE in the U.S., Janssen-Cilag is responsible for commercialization in Europe and the rest of the world. Janssen Pharmaceutical K.K. is responsible for commercialization in Japan. For a limited period of time, Millennium and Ortho Biotech Inc. are co-promoting VELCADE in the U.S. VELCADE is approved in more than 80 countries worldwide.

In the U.S., VELCADE is indicated for the treatment of patients with multiple myeloma who have received at least one prior therapy. VELCADE is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. VELCADE is contraindicated in patients with hypersensitivity to bortezomib, boron, or mannitol. VELCADE should be administered under the supervision of a physician experienced in the use of antineoplastic therapy. In the European Union and many other countries worldwide, VELCADE is approved for patients with multiple myeloma after first relapse.

Risks associated with VELCADE therapy include new or worsening peripheral neuropathy, hypotension observed throughout therapy, cardiac and pulmonary disorders, gastrointestinal adverse events, thrombocytopenia, neutropenia and t
'/>"/>

SOURCE Millennium Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... 3, 2015  This industry report package offers the most up-to-date market ... glass in the world and in the top 10 global countries. Along ... from the following countries: Australia , ... , Italy , Japan , ... United Kingdom , United States ...
(Date:3/3/2015)... , March 3, 2015  UnaliWear announces the market ... support for seniors that guards against wandering and provides ... The new wearable – the Kanega watch ( http://www.UnaliWear.com ... to use an easy speech interface rather than buttons, ... without human input. The watch goes ...
(Date:3/3/2015)... , March 3, 2015  Columbia Laboratories, Inc. (Nasdaq: ... or "the Company"), a specialty pharmaceutical company focused on ... present at the 27th Annual ROTH Conference, which will ... Niguel in Dana Point, California . ... at 9:00 a.m. Pacific Time (12:00 p.m. Eastern Time) ...
Breaking Medicine Technology:Global Safety Glass Market to 2019 - Market Size, Top 10 Countries, Trends, and Forecasts 2UnaliWear's Wearable For Seniors Extends Independence With Advanced Technology 2
... , , , , ... 12 QualTech Laboratorie s , Inc. , ... , and quality control measures , announced today that they ... assay for potency. This anti-factor IIa assay is a required component of the ...
... , MINNEAPOLIS, Aug. 11 ProUroCare Medical, Inc. ... of the required three centers in its FDA clinical study of ... , , ProUroCare began the current study with ... and having more than 40 patients enrolled overall. Since beginning, ...
Cached Medicine Technology:QualTech Laboratories Validates USP Protocols for Anti-Factor IIa Chromogenic Assay for Potency 2ProUroCare Medical Completes Clinical Trial at Second Study Site Using Digital Prostate Imaging Technology 2ProUroCare Medical Completes Clinical Trial at Second Study Site Using Digital Prostate Imaging Technology 3
(Date:3/3/2015)... (PRWEB) March 03, 2015 The ... public’s expectation of excellence in care and safe practice ... position of the RNS that biologic infusions are administered ... the direct supervision of a registered nurse (RN), as ... including anaphylaxis can occur in patients receiving these medications ...
(Date:3/3/2015)... March 03, 2015 In March, 1% ... networks, will kick off a new campaign, “Know Your Source,” ... businesses, nonprofits, and ambassadors in their quest for ingredient awareness ... with several of its members and partners, including King Arthur ... Once network, to raise awareness for food as an environmental ...
(Date:3/3/2015)... (PRWEB) March 04, 2015 The report ... on the therapeutic development for Alopecia. Alopecia is the ... the two main types of alopecia. Causes for alopecia ... Symptoms of alopecia may include male pattern hair loss, ... hair. Alopecia can be classified as focal or diffuse ...
(Date:3/3/2015)... US Air Purifiers LLC , an Illinois based company ... announce that all Rabbit brand air purifiers are back in ... coast port strikes. This news comes just in time, as ... The port strikes, which have caused significant supply difficulties ... by as much as 1%, have hindered the restocking capabilities ...
(Date:3/3/2015)... Daylight Savings Time may lead to your kids to ... parents. , Parents and their children may feel a bit ... set their clocks forward one hour for Daylight Savings Time. ... hour earlier -- you will have already lost one hour ... “sleep hygiene” for their kids and teens this week, says ...
Breaking Medicine News(10 mins):Health News:Administration of Biologic Infusions: A Position Statement of the Rheumatology Nurses Society 2Health News:1% For the Planet Asks Consumers to “Know Your Source” 2Health News:Alopecia Therapeutics Drugs and Companies Pipeline Market H1 2015 Review Report Available at RnRMarketResearch.com 2Health News:Alopecia Therapeutics Drugs and Companies Pipeline Market H1 2015 Review Report Available at RnRMarketResearch.com 3Health News:Alopecia Therapeutics Drugs and Companies Pipeline Market H1 2015 Review Report Available at RnRMarketResearch.com 4Health News:Rabbit Air Purifiers Back In Stock at US Air Purifiers LLC 2Health News:Rabbit Air Purifiers Back In Stock at US Air Purifiers LLC 3Health News:Don’t Let Daylight Savings Disrupt Your Child’s Sleep 2
... Win Patient Safety Protections, OAKLAND, Calif., ... University of California medical centers throughout the ... majority, the California Nurses Association,announced today. The ... as resolving long-standing issues of pension and ...
... serious trauma live, often with little visible damage, surgeons say ... of war in Iraq, there,s some relatively good medical ... are now surviving injuries that would have been fatal in ... The Journal of Craniofacial Surgery , the surgical and treatment ...
... Mich., March 24 Perrigo Company,(Nasdaq: PRGO ... CEO Joseph,C. Papa will present at the 12th ... March 25, at 2:05 p.m. (ET) at the,Grand ... Company is a leading global healthcare supplier that ...
... Fitness,Corporation (OTC Bulletin Board: HFIT) today announced that ... repurchase up to $2.5 million of the,company,s outstanding ... shares on the open market in amounts and ... with Securities and Exchange,Commission Rule 10b-18 and other ...
... urged to discuss risk factors with their doctors, ... long been known that,psoriasis, a chronic skin condition ... bleed, can have a significant negative impact on ... finding that,psoriasis, especially severe psoriasis, is linked with ...
... International,Corporation (Nasdaq: PRXL ) announced today it will ... Conference. James Winschel, Senior Vice,President and Chief Financial Officer ... a.m. ET on Thursday, March 27, 2008., A ... the,"Investor Relations Webcasts" section of PAREXEL,s web site at, ...
Cached Medicine News:Health News:UC RNs Overwhelmingly Approve New Contract 2Health News:UC RNs Overwhelmingly Approve New Contract 3Health News:Innovative Care Is Helping Iraq War's Injured Survive 2Health News:Innovative Care Is Helping Iraq War's Injured Survive 3Health News:Health Fitness Announces $2.5 Million Stock Repurchase Plan 2Health News:Research Shows Patients With Psoriasis at Increased Risk for Developing Other Serious Medical Conditions 2Health News:Research Shows Patients With Psoriasis at Increased Risk for Developing Other Serious Medical Conditions 3Health News:Research Shows Patients With Psoriasis at Increased Risk for Developing Other Serious Medical Conditions 4Health News:PAREXEL International to Present at Bank of America 2008 Smid Cap Conference 2
Anodized aluminum. Durable and lightweight with built-in protection against rust. Security locks ensure against accidental opening. Silicone matting/V-strips and bumper guards hold instruments in pla...
Diamond knife tray with silicone inserts to securely hold the diamond knife....
Size: 6 x 10 inches. Depth: 7 inches. Sterilizable plastic tray with silicone matting for supporting and protecting instruments....
Straight sharp round blade. Flat serrated handle with polished finish....
Medicine Products: